Differences in health care access may drive prostate cancer disparities
October 31st 2023“It was interesting to find that when Black and White men were provided equal access to the same therapies, given at the same dosage and monitored in the same setting, disparities in outcomes were eliminated," says Jun Gong, MD.
Private equity acquisition is linked with lower MIPS scores for urologists
October 23rd 2023“As private equity firms increasingly engage in urology, key stakeholders, including policymakers and urologists, need to ensure that the quality of care is not compromised with the structural changes implemented after acquisition," write the authors.
Niraparib/abiraterone combo associated with survival benefit in BRCA+ mCRPC
October 22nd 2023Adding niraparib to abiraterone acetate and prednisone (AAP) was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.
Phase 3 trial of subcutaneous nivolumab in ccRCC meets co-primary end points
October 19th 2023Data showed noninferiority of subcutaneous nivolumab to intravenous nivolumab in the time-average to nivolumab serum concentration over 28 days (Cavgd28) and the trough serum concentration at steady state (Cminss).
Electrofulguration shows long-term efficacy for UTIs in menopausal women
October 11th 2023“These findings demonstrate that electrofulguration provides a durable clinical cure that enables many postmenopausal women to remain UTI-free with minimal to no continued need for antibiotic therapy," says Philippe E. Zimmern, MD.